Skip to Content

'
Ralph G. Zinner, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
Department of Investigational Cancer Therapeutics
1515 Holcombe Blvd.
Unit Number: 455
Houston, TX 77030
Room Number: FC8.2036
Phone: (713) 745-6601
Fax: (713) 794-4130
Email: rzinner@mdanderson.org

Education & Training

Degree-Granting Education

1993 Georgetown University School of Medicine, Washington, DC, MD, Internal Medicine
1986 University of California Berkley, Berkley, CA, BA, Japanese Language

Postgraduate Training

7/1996-6/1999 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1993-6/1996 Clinical Residency, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA

Board Certifications

2011 American Board of Internal Medicine (Medical Oncol) Diplomat

Experience/Service

Academic Appointments

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-2011

Selected Publications

Peer-Reviewed Original Research Articles

1. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 6/2011. e-Pub 1/2010. PMID: 20094773.
2. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small-cell lung cancer treated in a phase I clinic. Oncologist 16(3):327-35, 2011. e-Pub 2/2011. PMID: 21339262.
3. Zinner RG, Saxman SB, Peng G, Monberg MJ, Ortuzar WI. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin Lung Cancer 11(5):352-7, 9/2010. PMID: 20837462.
4. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol 33(2):148-52, 4/2010. PMID: 19687727.
5. Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clin Lung Cancer 11(2):126-31, 3/2010. PMID: 20199979.
6. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 28(4):614-9, 2/2010. e-Pub 10/2009. PMCID: PMC2815996.
7. Zinner R. Gene-based therapy: novel approaches. J Thorac Oncol 4(11 Suppl 3):S1086-9, doi: 10.1097/01.JTO.0000361761.19199.6e, 11/2009. PMID: 19861928.
8. Zinner RG, Barrett BL, Popova E, Damien P, Volgin AY, Gelovani JG, Lotan R, Tran HT, Pisano C, Mills GB, Mao L, Hong WK, Lippman SM, Miller JH. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther 8(3):521-32, 3/2009. e-Pub 3/2009. PMID: 19276160.
9. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 73(1):119-27, 1/2009. e-Pub 6/2008. PMID: 18556142.
10. Lewin JS, Zinner RG. Images in clinical medicine. Reversal of laryngeal paresis. N Engl J Med 357(23):e25, e25, 12/2007. e-Pub 12/2007. PMID: 18057332.
11. William WN, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol 2(8):745-50, 8/2007. PMID: 17762342.
12. Zinner RG, Nemunaitis J, Eiseman I, Shin HJ, Olson SC, Christensen J, Huang X, Lenehan PF, Donato NJ, Shin DM. Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 13(10):3006-14, 5/2007. PMID: 17505003.
13. Altundag O, Stewart DJ, Fossella FV, Ayers GD, Wei W, Zhou X, Zinner RG. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2(2):141-6, 2/2007. PMID: 17410030.
14. Chiappori AA, Ellis PM, Hamm JT, Bitran JD, Eiseman I, Lovalvo J, Burnett D, Olson S, Lenehan P, Zinner RG. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 1(9):1010-19, 11/2006. PMID: 17409987.
15. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-69, 9/2006. PMID: 16943532.
16. Bruzzi JF, Truong M, Zinner R, Erasmus JJ, Sabloff B, Munden R. Short-term restaging of patients with non-small-cell lung cancer receiving chemotherapy. J Thorac Oncol 1(5):452-9, 6/2006. PMID: 17409894.
17. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 3/2006. PMID: 16640804.
18. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 12/2005. PMID: 16258975.
19. Papadimitrakopoulou V, Agelaki S, Tran HT, Kies M, Gagel R, Zinner R, Kim E, Ayers G, Wright J, Khuri F. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. Clin Cancer Res 11(11):4151-9, 6/2005. PMID: 15930351.
20. Nemunaitis J, Eiseman I, Cunningham C, Senzer N, Williams A, Lenehan PF, Olson SC, Bycott P, Schlicht M, Zentgraff R, Shin DM, Zinner RG. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 11(10):3846-53, 5/2005. PMID: 15897585.

Last updated: 7/23/2014